Foghorn Therapeutics reports the dosing of its first patient in a Phase 1 trial of FHD-909, a novel oral inhibitor targeting SMARCA2 for solid tumors with SMARCA4 mutations.

TREMFYA® (guselkumab) shows remarkable outcomes in patients with Crohn's disease and ulcerative colitis, both those who haven't received biologics and those who have not responded to them.

Pfizer has revealed encouraging topline findings from the final pre-specified overall survival (OS) assessment of the TALAPRO-2 trial involving TALZENNA® (talazoparib).

Xencor showcases early research findings on XmAb942, a powerful long-lasting anti-TL1A antibody aimed at treating inflammatory bowel diseases.

Arialys Therapeutics has dosed the initial participants in a Phase 1 clinical trial for ART5803, a targeted therapy aimed at autoimmune neuropsychiatric disorders.

Kymera Therapeutics has received FDA approval for the Investigational New Drug Application of KT-621, an innovative oral STAT6 degrader.

InnoCare Pharma announced that their phase II trial of the TYK2 inhibitor ICP-488 met its primary goal in adults with moderate-to-severe plaque psoriasis.

Bayer has revealed that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for the investigational drug elinzanetant.

Teva's biosimilar of Prolia® (denosumab) has been submitted for review by the U.S. FDA and EU EMA. Prolia® is used for treating specific conditions that increase the risk of complications.

ImmuneSensor Therapeutics has begun dosing in its Phase 1 clinical trial for its primary cGAS inhibitor candidate, IMSB301.

Phanes Therapeutics has reported that the initial patient has been treated in a clinical trial involving PT886 alongside KEYTRUDA® (pembrolizumab).

Blue Earth Therapeutics pushes forward with the clinical development of Lutetium (177Lu) rhPSMA-10.1 injection, showing encouraging Phase 1 results.